Showing posts with label Insulin. Show all posts
Showing posts with label Insulin. Show all posts

Tuesday, November 03, 2009

HbA1c better predictor retinopathy than FPG in US population



According to a
study published in Diabetes Care, glycated hemoglobin (HbA1c) is a better predictor of retinopathy prevalence in the general population than fasting plasma glucose (FPG).
Diabetes is a disease that occurs when the pancreas does not secrete enough insulin or the body is unable to process it properly. Insulin is the hormone that regulates the level of sugar (glucose) in the blood. Diabetes can affect children and adults. Patients with diabetes are more likely to develop eye problems such as cataract or glaucoma., but the main threat to vision is its effect on the retina.

Researchers analyzed data from 1,066 people, including values for HbA1c, FPG, and 45 degree color digital retinal images. After using area under the receiver operator curve analysis...the team found that HbA1c was a significantly stronger discriminator of retinopathy than FPG.

While diabetic retinopathy, or more specifically its associated threshold FPG value of 7.0 mmol/l, has been used in diagnostic criteria for type 2 diabetes by the American Diabetes Association, this study confirms...that HbA1c levels could be a superior measure for predicting retinopathy risk to FPG and may be more appropriate for use in diagnosing type 2 diabetes, the authors said.

Cheng et al conclude: “While the HbA1c and FPG levels of 5.5% and 5.8 mmol/l provide start points at which retinopathy prevalence increases most precipitously, HbA1c appears to discriminate between the presence and absence of retinopathy at least as well as FPG and offers some advantages over FPG.”
Reblog this post [with Zemanta]

Tuesday, June 30, 2009

Experiment seeks to head off Type 1 diabetes

Researchers at Children's Hospital of Pittsburgh are hoping to control type 1 diabetes by curbing the rogue immune cells that cause it, before patients become completely dependent on daily insulin injections tosurvive.

About 3 million Americans have Type 1 diabetes, where the body mistakenly attacks and destroys cells in the pancreas that produce insulin, the hormone crucial to converting blood sugar to energy.

This novel vaccine -- made from patients' own blood blocks the '911 call' that dendritic cells send to direct T cells to the pancreas. Just altering three communication molecules on their surface basically confuses and paralyzes the T cells. In mice and monkeys, the reprogrammed cells ended the vicious cycle of a pancreas attack that in turn attracts more T cells to attack again.

In human trials, the team has used donated blood to filter out immature dendritic cells and then reprogram them. Animal experiments have shown that after the cells have been re-injected just inside the skin over the pancreas...the cells somehow find their way back to that organ to start working.

Two competing teams - MacroGenics Inc. and Eli Lilly, and Tolerx Inc. and GlaxoSmithKline - have advanced tests under way

Currently, 15 adult diabetics [are] being injected to make sure there are no unexpected side effects before researchers test if reprogrammed cells might really protect children's pancreas cells

Reblog this post [with Zemanta]

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review